Denosumab News
Most Popular Denosumab Story
Emerging markets figure in Glaxo-Amgen deal
GlaxoSmithKline is betting that Amgen gets the A-OK for denosumab in Europe and beyond. The U.K. drugmaker is paying Amgen $120 million plus royalties for the right to market the osteoporosis med in Read more...
Latest Headlines
- May 24, 2011
- December 14, 2010
- November 19, 2010
- June 18, 2010
- May 28, 2010
- July 28, 2009
- November 10, 2008
- November 7, 2008
- September 10, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
